NICE Recommends Amgen’s Vectibix for Metastatic Colorectal Cancer

The U.K.’s National Institute for Health and Care Excellence has published a final appraisal recommending Vectibix as an option for adult patients with previously untreated, RAS wild-type metastatic colorectal cancer in combination with certain chemotherapy regimens.

The final appraisal is not NICE’s final guidance for the drug, which is expected to be delivered to the National Health Service in April.